← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT06025630

Targeting Endoplasmic Reticulum Stress in Human Hypertension

Trial Parameters

Condition Hypertension
Sponsor University of North Texas Health Science Center
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 70
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2023-08-15
Completion 2028-12-31
Interventions
TUDCAPlacebo

Brief Summary

There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.

Eligibility Criteria

Inclusion Criteria: 1. 18 to 80 years of age 2. No tobacco/nicotine use within preceding 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches) 3. Systolic blood pressure \<140 mmHg; diastolic blood pressure \<90 mmHg (obtained at the Screening and Familiarization Visit) 4. Normal 12-lead ECG (obtained at the Screening and Familiarization Visit and reviewed by a board-certified physician) 5. Normal clinical results from a medical exam reviewed by a board-certified physician (e.g., General Health Questionnaire obtained at the Screening and Familiarization Visit) 6. Body mass index (BMI) \<35 unless athletic/muscular build; calculation = body weight (kg)/height (m2); 7. Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions unless post-menopausal Exclusion Criteria: 1. Not meeting the defined age criteria 2. Body mass index (BMI) \>35 unless athletic/muscular build; calculation = body weight (kg)/height (m2) 3. Any t

Related Trials